| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc. | RP-L301 | Pyruvate Kinase Deficiency (PKD) | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| Rocket Pharmaceuticals Inc. | RP-A501 | Danon disease | Phase 2 | Hold Removed | Intravenous | Genetic Disorder |
| Rocket Pharmaceuticals Inc. | Trabodenoson and latanoprost | Glaucoma | Phase 2 | Trial Discontinued | Ocular | Opthalmic |
| Roivant Sciences Ltd. | Brepocitinib - (NEPTUNE) | Non-infectious uveitis (NIU) | Phase 3 | Data Released | Oral | Opthalmic |
| Roivant Sciences Ltd. | Batoclimab | Thyroid Eye Disease (TED) | Phase 3 | Ongoing | Intravenous | Opthalmic |
| Roivant Sciences Ltd. | Batoclimab | Myasthenia Gravis (MG) | Phase 3 | Data Released | Intravenous | Neurology |
| Roivant Sciences Ltd. | ADORING 2 | Atopic Dermatitis | Phase 3 | Data Released | Oral | Immunology |
| Roivant Sciences Ltd. | Batoclimab | Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | Phase 2b | Data Released | Intravenous | Neurology |